|
Active substance |
olaratumab |
|
Holder |
S.A. Eli Lilly N.V. |
|
Status |
Closed |
|
Indication |
in combination with doxorubicin for the treatment Advanced soft tissue sarcoma not amenable to curative treatment with surgery or radiotherapy and not previously treated with doxorubicin |
|
Public documents |
|
|
Last update |
31/01/2018 |
Lartruvo®
Last updated on 13/09/2024